|FT500 is an off-the-shelf, iPSC-derived NK cell product that can bridge innate and adaptive immunity, and has the potential to overcome multiple mechanisms of immune checkpoint inhibitor (ICI) resistance. The preclinical data provide compelling evidence supporting the clinical investigation of FT500 as monotherapy and in combination with ICI in participants with advanced solid tumors.
|Clinical trials phase
|Start date (estimated)
|End date (estimated)
|Advanced Malignant Solid Neoplasm
|A malignant solid neoplasm that has spread extensively to other anatomic sites or is no longer responding to treatment.
|Other study identifiers
|Which differentiated cell type is used
|natural killer cell
|A lymphocyte that can spontaneously kill a variety of target cells without prior antigenic activation via germline encoded activation receptors and also regulate immune responses via cytokine release and direct contact with other cells.
|Estimated number of participants